Skip to main
COO

Cooper Companies (COO) Stock Forecast & Price Target

Cooper Companies (COO) Analyst Ratings

Based on 14 analyst ratings
Hold
Strong Buy 14%
Buy 21%
Hold 57%
Sell 0%
Strong Sell 7%

Bulls say

Cooper Companies is viewed positively because its two businesses provide a balanced and durable growth profile, with CooperVision supported by a broad contact lens franchise spanning spherical, multifocal, toric, and specialty lenses that commands roughly one fourth of the US market, while CooperSurgical brings leading exposure to fertility, women’s care, and Paragard, which holds 17% of the US IUD market. The company also shows attractive financial resilience, with gross margin of 66.7%, operating margin of 26.3% up 30 bps Y/Y and above consensus, and management raising FY26 free cash flow guidance to $650M, all of which support operating leverage, debt reduction, and lower interest expense. Even though CooperVision growth has been uneven due to APAC softness and US channel destocking, the outlook remains constructive because management expects these pressures to ease, fertility trends are improving, and the company is still positioned to sustain mid-single digit organic revenue growth and high-single digit or better EPS growth.

Bears say

Cooper Companies is facing a negative outlook because the core investment case depends on mid- to high-single-digit organic growth and expanding margins, yet CooperSurgical has already shown slowing momentum, with sales of $349M missing the $356M consensus and organic growth decelerating to 3% from 6% in F2Q26. The weakness is especially concerning because office and surgical revenue grew only 2% organic, fertility revenue rose just 5%, PARAGARD was flat year over year at $43M, and management had to lower FY26 CSI revenue guidance to $1.401-1.410B from $1.402-1.414B after softer capital equipment sales hurt fertility. On top of that, the company faces increasing competition in contact lenses, consumer weakness, currency headwinds, and skepticism that MyDay MiSight can overcome affordability barriers, while valuation support is pressured by medtech multiple compression despite estimated FCF of $887M and a broader thesis that depends on stronger EPS growth than the current operating trends appear to justify.

Cooper Companies (COO) has been analyzed by 14 analysts, with a consensus rating of Hold. 14% of analysts recommend a Strong Buy, 21% recommend Buy, 57% suggest Holding, 0% advise Selling, and 7% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cooper Companies and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cooper Companies (COO) Forecast

Analysts have given Cooper Companies (COO) a Hold based on their latest research and market trends.

According to 14 analysts, Cooper Companies (COO) has a Hold consensus rating as of Oct 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $71.21, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $71.21, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cooper Companies (COO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.